Incidence of Ipsilateral side Recurrence after Open or VATS resection of colorectal lung metastases
ConclusionsNo significant difference was observed in IR rates between VATS and open surgery in the treatment of colorectal cancer lung metastases.
Conclusion Based on the RR, Conv R, and symptom palliation ability, mFOLFOXIRI+α was suggested to be a viable candidate for first-line treatment for patients with ARCC, especially those with a high tumor burden. PMID: 32074573 [PubMed - as supplied by publisher]
AbstractColorectal cancer (CRC) refers to a deadly carcinoma following potent invasiveness and metastasis in advanced stage. Unfortunately, existing anti ‐CRC medicine is insufficient for chemotherapy in addition to adverse effects. Consequently, the candidate natural ingredient for treating CRC needs to be further developed. Our previous experiments report that genistein exerts beneficial effects to inhibit CRC cells via an antiproliferative mecha nism. Based on the metastatic characteristics of staging CRC, anti‐invasive and antimetastatic pharmacological activities using genistein remain uninvestigated. The scientif...
Publication date: 25 April 2020Source: Journal of Industrial and Engineering Chemistry, Volume 84Author(s): Nea Young Chun, Se-Na Kim, Youn Seo Choi, Young Bin ChoyAbstractColorectal cancer is the second leading cause of cancer-related deaths worldwide. CRC is often treated with intravenous 5-fluorouracil (5FU). However, 5FU frequently shows low therapeutic efficacy and serious adverse events. Particulate drug carriers able to enhance intracellular delivery could be advantageous, since higher 5FU concentrations would be engulfed by cancer cells during a relatively short residence within the rectal space to improve local an...
ConclusionPerforming a colon conduit in patients undergoing total pelvic exenteration for LARC or LRRC avoids the risks of ileo-ileal anastomotic leakage and may reduce the risk of a post-operative ileus. Besides, there are no other differences in outcome for ileal and colon conduits.
We present our experience of sequential Y90 RE and portal vein embolization.
Clinical efficacy of Yttrium-90 (Y90) radioembolization (TARE) for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) is limited by extrahepatic disease progression, which may occur while patients are treated with sequential lobar TARE. TAS-102 (trifluride and tipiracil) has overall survival benefit for patients with refractory mCRC and may be a radiosensitizer. We aimed to evaluate the safety of the combination of TAS-102 and Y90 resin TARE in a Phase I dose-escalation trial.
This study assessed the efficacy of adding Y90 radioembolization to systemic therapy in patients with metastatic colorectal cancer to the liver.
To quantify the expression of co-inhibitory and functional molecules by tumor infiltrating CD8+ T cells in a murine heterotopic colorectal cancer model after combinational therapy of cryoablation with a dual immune checkpoint blockade (DICB).
Microwave ablation (MWA) has been shown to be effective in treatment of primary hepatic cellular carcinoma (HCC) and liver metastasis from colorectal cancer. The purpose of this study is to demonstrate the safety and efficacy of MWA of liver lesions including primary HCC and liver metastasis with final ablation zone that is ≤ 5 mm from the pericardium.
Right-sided primary (RSP) metastatic colorectal cancer (mCRC) is a poor prognostic factor compared with left-sided primary (LSP) tumor. No overall survival (OS) benefit was seen with transarterial radioembolization (TARE) as a first line therapy in the SIRFLOX, FOXFIRE Global, and FOXFIRE studies. However, a metaanalysis demonstrated a survival advantage for RSP patients. Little data exists between RSP and LSP outcomes when TARE is used as second- or third-line therapy. This retrospective analysis offers preliminary data on the differences between RSP and LSP mCRC treated with TARE.